Clinical Trials for Arthritis

433 arthritis trials indexed, 164 currently recruiting. Updated daily from ClinicalTrials.gov.

Understanding Arthritis

Arthritis is a broad term that describes inflammation of one or more joints. The condition affects the tissues around the joints, including cartilage, synovium, and bone. In arthritis, the immune system may mistakenly attack joint tissues, or wear and tear may cause cartilage breakdown. Doctors diagnose arthritis through a combination of physical exams, patient history, blood tests, and imaging studies like X-rays or MRIs. These tools help identify the type of arthritis and the extent of joint damage.

Common symptoms of arthritis include joint pain, stiffness, swelling, and reduced range of motion. These symptoms often worsen with activity or after periods of rest. Arthritis can begin at any age but is most common in people over 50 years old. Women are more likely to develop certain types, such as rheumatoid arthritis, while men may have higher rates of gout. Risk factors include genetics, obesity, previous joint injuries, and repetitive joint use in work or sports.

Arthritis is a major cause of disability worldwide and has a significant impact on quality of life. In the United States, about 58.5 million adults have doctor-diagnosed arthritis, which is nearly one in four people. The condition also leads to substantial economic costs, including medical expenses and lost work productivity. Understanding arthritis is important because it affects daily activities, mobility, and independence for millions of individuals.

The Arthritis Treatment Landscape

The first-line treatment for arthritis usually focuses on symptom relief and improving joint function. Nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen or naproxen are commonly used to reduce pain and inflammation. Physical therapy and lifestyle changes like weight management and exercise are also important early steps. These treatments are often combined and adjusted based on symptom severity and patient response.

When first-line treatments do not provide sufficient relief, doctors may recommend second- or third-line options. These include disease-modifying antirheumatic drugs (DMARDs) for inflammatory arthritis types. Methotrexate is a widely used DMARD that slows disease progression. Biologic drugs targeting specific immune pathways, such as tumor necrosis factor (TNF) inhibitors, are another option for patients with moderate to severe disease. Corticosteroids may be used short-term to control flares but are not recommended for long-term use due to side effects.

Despite available treatments, some patients do not respond well or experience significant side effects. For example, older adults and those with comorbidities may have limited options due to drug interactions or intolerance. Resistance to certain medications can also develop over time. Current research aims to find new therapies that are safer, more effective, and tailored to individual patient needs. This includes exploring novel drug targets and personalized medicine approaches.

Why Clinical Trials Matter for Arthritis

Clinical trials offer patients access to new treatments that are not yet widely available. Participating in a trial can provide closer medical monitoring and contribute valuable information to arthritis research. ClinicalTrials.gov currently lists 433 arthritis clinical trials, with 164 actively recruiting participants. These studies cover a range of interventions, including medications, physical therapies, and lifestyle strategies. Joining a trial may help advance knowledge and improve future care for arthritis patients.

It is important to understand that clinical trials carry risks. The safety and effectiveness of new treatments are not fully known at the start of a study. Some trials include placebo groups, meaning participants might not receive the experimental treatment. Additional clinic visits and tests are often required, which can be time-consuming. Side effects may occur, and patients should discuss these factors carefully with their healthcare providers before enrolling.

Clinical trials for arthritis are sponsored by a variety of organizations, including academic institutions, pharmaceutical companies, and cooperative research groups. These sponsors work together to ensure trials meet scientific and ethical standards. ClinicalTrials.gov serves as a central registry that provides detailed information about ongoing and completed trials. This database helps patients, caregivers, and healthcare professionals find relevant studies and stay informed about research progress.

What to Look for in a Arthritis Clinical Trial

Clinical trials are organized into phases that test different aspects of new treatments. Phase 1 trials focus on safety and dosing, often involving a small number of participants. Phase 2 trials evaluate effectiveness and side effects, usually with more participants. Phase 3 trials compare the new treatment to standard care in larger groups. Phase 4 trials occur after approval, monitoring long-term effects. For arthritis, many trials do not specify a phase (166 trials). Phase 2 trials are the most common with 53, followed by 47 each in Phase 1 and Phase 3. This mix shows a balanced effort to test safety, effectiveness, and comparison to current treatments.

Inclusion criteria for arthritis clinical trials often focus on specific patient characteristics. Age ranges can vary but commonly include adults from 18 to 75 years old. Some trials require participants to have a confirmed diagnosis of a particular type of arthritis, such as rheumatoid arthritis or osteoarthritis. Prior treatments might be considered; for example, some studies include patients who have tried standard medications without success. Biomarkers or lab tests may be needed to confirm disease activity or inflammation levels. Disease duration is another factor, with some trials focusing on early-stage arthritis and others on long-term cases.

Exclusion criteria help protect patients and ensure clear study results. Common reasons for exclusion include the presence of other serious health conditions like heart disease or uncontrolled diabetes. These comorbidities can increase risks or affect how the treatment works. Drug interactions are also a concern; patients taking certain medications may be excluded to avoid harmful effects. Safety thresholds such as kidney or liver function tests can disqualify some participants to prevent complications. These criteria help keep trials safe and focused on the target patient group.

From a patient perspective, practical considerations are important when joining a trial. The length of the trial can range from a few weeks to several months or longer. Visit schedules may require frequent trips to the study site, which could be challenging for some patients. Travel distance and costs should be discussed upfront. Patients should ask the research team key questions: What are the possible side effects? How often will I need to visit? Will I have access to the treatment after the trial? What happens if I decide to leave the study early? Clear answers help patients make informed decisions about participation.

Primary Sources and Further Reading

For those interested in learning more about arthritis and clinical trials, reliable sources offer detailed information. These resources cover arthritis symptoms, treatment options, and how clinical studies work. Patients and caregivers can use these links to find trustworthy guidance and support.

Latest Research and Emerging Treatments for Arthritis (2026)

Recent arthritis research is exploring new drugs that target both symptoms and underlying factors like weight and inflammation. For example, the medicine NNC0487-0111 (NCT07481630) is being tested as a once-weekly injection for adults with knee osteoarthritis who also have excess body weight. This drug aims to help reduce both weight and knee pain. By addressing weight, which can worsen joint stress, this treatment could improve daily function and comfort for many patients. Similarly, Eli Lilly is studying Eloralintide (NCT07353931) and Orforglipron (NCT07153471), two drugs also given once weekly to overweight or obese adults with knee osteoarthritis. These drugs may help manage pain while supporting weight loss, which is a key factor in arthritis management.

Other new drugs for arthritis focus on controlling inflammation in different types of arthritis. Tildrakizumab (NCT04314531) is being tested in patients with active psoriatic arthritis who have not used anti-TNF drugs before. This drug belongs to a class called IL-23 inhibitors, which may reduce inflammation by blocking certain immune signals. Another study is looking at a combination of baricitinib and anti-TNF therapy (NCT04870203) for rheumatoid arthritis patients who have not responded well to previous treatments. Baricitinib is a JAK inhibitor that works by interfering with pathways involved in inflammation. Combining it with anti-TNF drugs could better reduce disease activity for some patients.

These arthritis new treatments in 2026 reflect a growing focus on personalized approaches. By targeting specific causes like inflammation or excess weight, these drugs may offer more options for managing arthritis symptoms. For patients, this could mean improved pain control, better mobility, and a higher quality of life. Ongoing Phase 3 trials will help determine how effective and safe these treatments are, potentially expanding the choices available for arthritis treatment in the near future.

Frequently asked questions about Arthritis trials

How do I find Arthritis clinical trials?

The authoritative source for Arthritis clinical trials is ClinicalTrials.gov, maintained by the U.S. National Library of Medicine. 433 arthritis studies are currently indexed. You can search by entering "arthritis" as the condition, then filter by recruiting status, phase, and location. TrialsAlert scans ClinicalTrials.gov daily for new arthritis trials and delivers a plain-language briefing every Friday explaining what changed.

What phase are most Arthritis trials in?

Across the 433 arthritis trials TrialsAlert indexes, the most common phase is Phase 2. Early-phase studies (Phase 1 and Phase 2) test safety and initial efficacy. Phase 3 trials compare a candidate treatment against the current standard of care in larger populations and generate the evidence regulators use to approve new therapies.

How many Arthritis clinical trials are currently recruiting?

As of the latest scan, 164 arthritis trials have a "Recruiting" status on ClinicalTrials.gov, out of 433 total indexed. The recruiting figure changes daily as studies open, fill enrollment, and close. TrialsAlert subscribers are notified when a new recruiting arthritis trial matches their tracked condition.

Stay informed about arthritis research

Get a weekly briefing with the trials that matter most.

Start monitoring arthritis trials